Dec 31, 2019

Penumbra Q4 2019 Earnings Report

Penumbra's Q4 2019 financial results were reported, showcasing revenue growth and increased operating income.

Key Takeaways

Penumbra, Inc. reported a 20.3% increase in revenue for the fourth quarter of 2019, reaching $145.3 million. The company's operating income also rose to $10.6 million, compared to $6.7 million in the same period of the previous year. Full year revenue grew by 23.0% to $547.4 million.

Total revenue reached $145.3 million, a 20.3% increase compared to Q4 2018.

Neuro product revenue increased by 15.4% to $85.4 million.

Vascular product revenue grew by 27.9% to $59.8 million.

Operating income increased to $10.6 million, compared to $6.7 million in Q4 2018.

Total Revenue
$145M
Previous year: $121M
+20.3%
EPS
$0.22
Previous year: $0.13
+69.2%
Gross Margin
67.6%
Previous year: 65.2%
+3.7%
Gross Profit
$98.1M
Previous year: $78.7M
+24.7%
Cash and Equivalents
$72.8M
Previous year: $67.9M
+7.3%
Free Cash Flow
-$3.22M
Previous year: $4.49M
-171.6%
Total Assets
$666M
Previous year: $515M
+29.3%

Penumbra

Penumbra

Penumbra Revenue by Segment

Penumbra Revenue by Geographic Location

Forward Guidance

Penumbra projects total revenue for 2020 to be in the range of $635 million to $645 million, which represents growth of 16% to 18% over last year. This outlook includes the impact of recent reimbursement changes in Japan. Excluding Japan, Penumbra projects revenue growth for 2020 to be above 20%.

Revenue & Expenses

Visualization of income flow from segment revenue to net income